Astaxanthin
Phase 3Small molecule
Astaxanthin is one of 46 small molecule programs targeting Humans. It is currently in Phase 3.
2
Indications
6
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Astaxanthin
SSheba Medical Center
Phase 3
Primaquine
SanofiPreclinical
Acanya
PfizerPreclinical
Prevacid
TakedaPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Innohep
Jazz PharmaceuticalsPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Zantac 150
CChattem
Preclinical
Mycifradin
PPharmacia and Upjohn
Preclinical
Ofev
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteoarthritis2 trials
Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis
Completed·—·Phase 2·NCT05437601·80 enrolled
Treatment1 trial
ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
Completed·—·Phase 2·NCT06429059·50 enrolled
Diabetic Neuropathy1 trial
The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient
Unknown status·—·Phase 2/3·NCT04689984·60 enrolled
Pneumonia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Astaxanthin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSheba Medical Center